Clinic Attendance for Medication Refills and Medication Adherence amongst an Antiretroviral Treatment Cohort in Uganda: A Prospective Study

Setor Kunutsor, John Walley, Elly Katabira, Simon Muchuro, Hudson Balidawa, Elizabeth Namagala, Eric Ikoona, Setor Kunutsor, John Walley, Elly Katabira, Simon Muchuro, Hudson Balidawa, Elizabeth Namagala, Eric Ikoona

Abstract

Background. Regular clinic attendance for antiretroviral (ARV) drug refills is important for successful clinical outcomes in HIV management. Methods. Clinic attendance for ARV drug refills and medication adherence using a clinic-based pill count in 392 adult patients receiving antiretroviral therapy (ART) in a district hospital in Uganda were prospectively monitored over a 28-week period. Results. Of the 2267 total scheduled clinic visits, 40 (1.8%) were missed visits. Among the 392 clients, 361 (92%) attended all appointments for their refills (regular attendance). Clinic attendance for refills was statistically significantly associated with medication adherence with regular attendant clients having about fourfold greater odds of achieving optimal (≥95%) medication adherence [odds ratio (OR) = 3.89, 95% CI: 1.48 to 10.25, exact P = .013]. In multivariate analysis, clients in age category 35 years and below were less likely to achieve regular clinic attendance. Conclusion. Monitoring of clinic attendance may be an objective and effective measure and could be a useful adjunct to an adherence measure such as pill counting in resource-constrained settings. Where human resource constraints do not allow pill counts or other time-consuming measures, then monitoring clinic attendance and acting on missed appointments may be an effective proxy measure.

References

    1. UNAIDS 2008 Report on the global AIDS epidemic. 2008, .
    1. Detels R, Muñoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Journal of the American Medical Association. 1998;280(17):1497–1503.
    1. Kunutsor S, Evans M, Thoulass J, et al. Ascertaining baseline levels of antiretroviral therapy adherence in uganda: a multimethod approach. Journal of Acquired Immune Deficiency Syndromes. 2010
    1. Wasswa H. Uganda runs out of antiretroviral drugs after shortfall in aid. BMJ. 2009;339:p. b3255.
    1. Turner BJ. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients. Journal of Infectious Diseases. 2002;185(2):S143–S151.
    1. Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS. 2009;23(9):1035–1046.
    1. Parienti JJ, Das-Douglas M, Massari V, et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. PLoS One. 2008;3(7) Article ID e2783.
    1. Stone VE. Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clinical Infectious Diseases. 2001;33(6):865–872.
    1. Osterberg L, Blaschke T. Adherence to medication. The New England Journal of Medicine. 2005;353(5):487–497.
    1. Liechty CA, Alexander CS, Harrigan PR, et al. Are untimed antiretroviral drug levels useful predictors of adherence behavior? AIDS. 2004;18(1):127–129.
    1. Farley J, Hines S, Musk A, Ferrus S, Tepper V. Assessment of adherence to antiviral therapy in HIV-infected children using the medication event monitoring system, pharmacy refill, provider assessment, caregiver self-report, and appointment keeping. Journal of Acquired Immune Deficiency Syndromes. 2003;33(2):211–218.
    1. Chalker J, Andualem T, Gitau L, et al. Adherence rates in Africa: how are we doing?. In: Proceedings of the 36th Annual Conference on Global Health; 2009; Washington, DC, USA. .
    1. Chalker J, Wagner A, Tomson G, et al. Urgent need for coordination in adopting standardized antiretroviral adherence performance indicators. Journal of Acquired Immune Deficiency Syndromes. 2010;53(2):159–161.
    1. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Annals of Internal Medicine. 1999;131(2):81–87.
    1. Rastegar DA, Fingerhood MI, Jasinski DR. Highly active antiretroviral therapy outcomes in a primary care clinic. AIDS Care. 2003;15(2):231–237.
    1. Chalker J, Andualem T, Minzi O, et al. Monitoring adherence and defaulting for antiretroviral therapy in 5 East African countries: an urgent need for standards. Journal of the International Association of Physicians in AIDS Care. 2008;7(4):193–199.
    1. Ross-Degnan D, Pierre-Jacques M, Zhang F, et al. Measuring adherence to antiretroviral treatment in resource-poor settings: the clinical validity of key indicators. BMC Health Services Research. 2010;10, article 42
    1. Catz SL, McClure JB, Jones GN, Brantley PJ. Predictors of outpatient medical appointment attendance among persons with HIV. AIDS Care. 1999;11(3):361–373.
    1. Birbeck GL, Chomba E, Kvalsund M, et al. Antiretroviral adherence in rural zambia: the first year of treatment availability. American Journal of Tropical Medicine and Hygiene. 2009;80(4):669–674.
    1. Levine AM, Richardson JL, Marks G, et al. Compliance with oral drug therapy in patients with hematologic malignancy. Journal of Clinical Oncology. 1987;5(9):1469–1476.
    1. Wood PR, Casey R, Kolski GB, McCormick MC. Compliance with oral theophylline therapy in asthmatic children. Annals of Allergy. 1985;54(5):400–404.
    1. Smith EO, Curb JD, Hardy RJ. Clinic attendance in the hypertension detection and follow-up program. Hypertension. 1982;4(5):710–715.
    1. Miller NH, Hill M, Kottke T, Ockene IS. The multilevel compliance challenge: recommendations for a call to action: a statement for healthcare professionals. Circulation. 1997;95(4):1085–1090.
    1. Cauldbeck MB, O’Connor C, O’Connor MB, et al. Adherence to anti-retroviral therapy among HIV patients in Bangalore, India. AIDS Research and Therapy. 2009;6, article 7
    1. Giordano TP, Gilford AL, White AC, et al. Retention in care: a challenge to survival with HIV infection. Clinical Infectious Diseases. 2007;44(11):1493–1499.
    1. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Annals of Internal Medicine. 2001;134(10):968–977.
    1. Calmy A, Pinoges L, Szumilin E, Zachariah R, Ford N, Ferradini L. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS. 2006;20(8):1163–1169.
    1. Ferradini L, Jeannin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. The Lancet. 2006;367(9519):1335–1342.
    1. Mugavero MJ, Lin HY, Willig JH, et al. Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clinical Infectious Diseases. 2009;48(2):248–256.
    1. Park WB, Choe PG, Kim SH, et al. One-year adherence to clinic visits after highly active antiretroviral therapy: a predictor of clinical progress in HIV patients. Journal of Internal Medicine. 2007;261(3):268–275.
    1. Krebs DW, Chi BH, Mulenga Y, et al. Community-based follow-up for late patients enrolled in a district-wide programme for antiretroviral therapy in Lusaka, Zambia. AIDS Care. 2008;20(3):311–317.
    1. Park WB, Kim JY, Kim S-H, et al. Self-reported reasons among HIV-infected patients for missing clinic appointments. International Journal of STD and AIDS. 2008;19(2):125–126.
    1. Jaffar S, Amuron B, Foster S, et al. Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial. The Lancet. 2009;374(9707):2080–2089.
    1. Oyugi JH, Byakika-Tusiime J, Charlebois ED, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. Journal of Acquired Immune Deficiency Syndromes. 2004;36(5):1100–1102.
    1. Laurent C, Diakhaté N, Fatou Ngom Gueye N, et al. The Senegalese government’s highly active antiretroviral therapy initiative: an 18-month follow-up study. AIDS. 2002;16(10):1363–1370.
    1. Byakika-Tusiime J, Oyugi J, Tumwikirize W, Katabira ET, Mugyeni PN, Bangsberg DR. Ability to purchase and secure stable therapy are significant predictors of non-adherence to antiretroviral therapy in Kampala, Uganda. In: Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections; 2003; Boston, Mass, USA.
    1. Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS. 2003;17(9):1369–1375.
    1. Kleeberger CA, Buechner J, Palella F, et al. Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study. AIDS. 2004;18(4):683–688.
    1. Wagner GJ, Kanouse DE, Koegel P, Sullivan G. Correlates of HIV antiretroviral adherence in persons with serious mental illness. AIDS Care. 2004;16(4):501–506.
    1. Wenger N, Gifford A, Liu H, et al. Patient characteristics and attitudes associated with antiretroviral (AR) adherence. In: Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago); 1999; Alexandria, Va, USA.
    1. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. Journal of Acquired Immune Deficiency Syndromes. 2000;23(5):386–395.
    1. Williams PL, Storm D, Montepiedra G, et al. Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection. Pediatrics. 2006;118(6):e1745–e1757.
    1. Haynes RB. Determinants of compliance: the disease and the mechanics of treatment. In: Haynes RB, Sackett DL, editors. Compliance in Health Care. Baltimore, Md, USA: Johns Hopkins University Press; 1979. pp. 49–62.
    1. Horne R. Adherence to medication, a review of existing research. In: Myers L, Midence K, editors. Adherence to Treatment in Medical Conditions. London, UK: Harwood Academic; 1998. pp. 285–310.
    1. Carrieri P, Cailleton V, Le Moing V, et al. The dynamic of adherence to highly active antiretroviral therapy: results from the French national APROCO cohort. Journal of Acquired Immune Deficiency Syndromes. 2001;28(3):232–239.
    1. Cohen AD, Kaplan DM, Kraus M, Rubinshtein E, Vardy DA. Nonattendance of adult otolaryngology patients for scheduled appointments. The Journal of Laryngology and Otology. 2007;121(3):258–261.
    1. Adams LA, Pawlik J, Forbes GM. Nonattendance at outpatient endoscopy. Endoscopy. 2004;36(5):402–404.
    1. Israelski D, Gore-Felton C, Power R, Wood MJ, Koopman C. Sociodemographic characteristics associated with medical appointment adherence among HIV-seropositive patients seeking treatment in a county outpatient facility. Preventive Medicine. 2001;33(5):470–475.
    1. Vitolins MZ, Rand CS, Rapp SR, Ribisl PM, Sevick MA. Measuring adherence to behavioral and medical interventions. Controlled Clinical Trials. 2000;21(5):188S–194S.
    1. Christensen DB. Drug-taking compliance: a review and synthesis. Health Services Research. 1978;13(2):171–187.
    1. Westfall UE. Methods for assessing compliance. Topics in Clinical Nursing. 1986;7(4):23–30.
    1. Grymonpre RE, Didur CD, Montgomery PR, Sitar DS. Pill count, self-report, and pharmacy claims data to measure medication adherence in the elderly. Annals of Pharmacotherapy. 1998;32(7-8):749–754.
    1. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clinical Infectious Diseases. 2002;34(8):1115–1121.
    1. Simoni JM, Frick PA, Pantalone DW, Turner BJ. Antiretroviral adherence interventions: a review of current literature and ongoing studies. Topics in HIV Medicine. 2003;11(6):185–198.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren